Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

  1. Prenen, H.
  2. Deva, S.
  3. Keam, B.
  4. Lindsay, C.R.
  5. Lugowska, I.
  6. Yang, J.C.
  7. Longo, F.
  8. de Miguel, M.
  9. Ponz-Sarvise, M.
  10. Ahn, M.-J.
  11. Gumus, M.
  12. Champiat, S.
  13. Italiano, A.
  14. Salas, S.
  15. Perets, R.
  16. Arslan, C.
  17. Cho, B.C.
  18. Evers, S.
  19. Boetsch, C.
  20. Marbach, D.
  21. Dejardin, D.
  22. Sleiman, N.
  23. Ardeshir, C.
  24. Richard, M.
  25. Charo, J.
  26. Kraxner, A.
  27. Keshelava, N.
  28. Teichgräber, V.
  29. Moreno, V.
  30. Show all authors +
Journal:
Clinical Cancer Research

ISSN: 1557-3265 1078-0432

Year of publication: 2024

Volume: 30

Issue: 14

Pages: 2945-2953

Type: Article

DOI: 10.1158/1078-0432.CCR-23-2677 GOOGLE SCHOLAR